Antibody-directed therapy of multidrug-resistant tumor cells.
The major obstacle to effective cancer chemotherapy is the resistance of tumor cells to cytostatic agents. Tumor cells frequently express a multidrug-resistance (MDR) phenotype. In an effort to devise new strategies to overcome MDR, antibody-directed approaches for the eradication of MDR cells have been developed. Experimental data have shown that multidrug-resistant tumor cells can be efficiently killed by monoclonal antibodies, immunotoxins, or bispecific antibodies. The current experimental results indicate that an antibody-directed therapeutic approach to eradication of MDR cells might be a promising adjunct to conventional chemotherapy of cancer patients.
Efferth
T
T
German Cancer Centre, Heidelberg.
Volm
M
M
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000818:Animals; D018033:Antibodies, Bispecific / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002352:Carrier Proteins / Q000276:immunology*; D017024:Chemotherapy, Adjuvant; D004351:Drug Resistance / Q000276:immunology; D000939:Epitopes; D066246:ErbB Receptors; D006801:Humans; D007167:Immunotherapy; D000922:Immunotoxins / Q000627:therapeutic use; D008562:Membrane Glycoproteins / Q000276:immunology*; D009363:Neoplasm Proteins / Q000276:immunology*; D009369:Neoplasms / Q000737:chemistry / Q000188:drug therapy / Q000628:therapy*; D014407:Tumor Cells, Cultured
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D018033:Antibodies, Bispecific; D000911:Antibodies, Monoclonal; D002352:Carrier Proteins; D000939:Epitopes; D000922:Immunotoxins; D008562:Membrane Glycoproteins; D009363:Neoplasm Proteins; D066246:ErbB Receptors